Parakkal Deepak

Medicine & Life Sciences

1. Inflammatory Bowel Diseases 100%
2. Crohn Disease 96%
3. Tumor Necrosis Factor Inhibitors 56%
4. United States Food and Drug Administration 34%
5. Ulcerative Colitis 32%
6. Magnetic Resonance Spectroscopy 31%
7. Tumor Necrosis Factor-alpha 26%
8. vedolizumab 24%
9. Ischemic Colitis 23%
10. Ustekinumab 21%
11. Tomography 17%
12. Therapeutics 17%
13. Mesalamine 16%
14. tofacitinib 15%
15. Restorative Proctocolectomy 14%
16. Bariatric Surgery 13%
17. Pouchitis 13%
18. Vaccines 13%
19. Non-alcoholic Fatty Liver Disease 12%
20. Inflammation 12%
21. Radiologists 11%
22. Safety 11%
23. sodium phosphate 11%
24. Immunologic Factors 10%
25. Severe Acute Respiratory Syndrome 10%
26. Coronavirus 10%
27. SARS Virus 9%
28. T-Cell Lymphoma 9%
29. Celiac Disease 9%
30. Systematic Reviews 8%
31. Rheumatoid Arthritis 8%
32. Chronic Disease 8%
33. Clinical Trials 8%
34. Vaccination 8%
35. Lawyers 8%
36. Confidence Intervals 8%
37. Biological Therapy 8%
38. Gastroenterologists 7%
39. Inpatients 7%
40. Endoscopy 7%
41. Inflammatory Bowel Disease 6 7%
42. Biological Products 7%
43. Lubiprostone 7%
44. Antibodies 6%
45. Messenger RNA 6%
46. Pharmaceutical Preparations 6%
47. Interleukin-23 6%
48. Etanercept 6%
49. Protons 6%
50. Drug-Related Side Effects and Adverse Reactions 6%